Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 1:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 33,035 matching trials from the live ClinicalTrials.gov search.
Completed Not applicable Interventional Accepts healthy volunteers Results available

Asthma in Central Texas Project

NCT01676896
Conditions
Asthma
Interventions
Asthma in-school class, Asthma Day Camp, Health Promotion in-school class
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
6 Years to 13 Years
Enrollment
292 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Austin, Texas
Conditions
Acute Leukaemia
Interventions
Daunorubicin, Cytarabine, Eltrombopag, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
14
States / cities
Farmington, Connecticut • Miami, Florida • Orlando, Florida + 11 more
Conditions
Healthy Volunteers
Interventions
Lanadelumab, Placebo
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
19 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Lincoln, Nebraska
Conditions
Pain, Neuropathic, Pain, Inflammatory
Interventions
AFA-281
Drug
Lead sponsor
Afasci Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Alamitos, California
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebos
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
12 Years to 17 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
29
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Fountain Valley, California + 25 more
Conditions
Ileus, Post-Operative Adhesions
Interventions
LB1148, Placebo
Drug
Lead sponsor
Palisade Bio
Industry
Eligibility
18 Years to 80 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
28
States / cities
Mobile, Alabama • Yuma, Arizona • Irvine, California + 20 more
Conditions
Ulcerative Colitis
Interventions
Vixarelimab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
15
States / cities
Camarillo, California • Los Angeles, California • Mission Hills, California + 12 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Hydromorphone on Responses to Verbal Tasks

NCT02205983
Conditions
Healthy
Interventions
2 mg hydromorphone, 1000 mg Acetaminophen, 4 mg hydromorphone, dextrose
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Myocardial Infarction, Cardiovascular Diseases, Pathologic Processes
Interventions
KAI-9803
Drug
Lead sponsor
KAI Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
17
States / cities
Huntsville, Alabama • Escondido, California • Torrance, California + 14 more
Conditions
Dysphagia
Interventions
Dexamethasone, Saline
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 80 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Morgantown, West Virginia
Conditions
Candidemia, Mycoses, Fungal Infection, Invasive Candidiases
Interventions
Rezafungin for Injection, Caspofungin, Fluconazole, intravenous placebo, oral placebo
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
19
States / cities
Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 16 more
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Glycopyrronium bromide, Placebo to glycopyrronium bromide, Tiotropium
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
1,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
75
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more
Completed Phase 3 Interventional Results available

Levodopa for the Treatment of Residual Amblyopia

NCT01190813
Conditions
Amblyopia
Interventions
Levodopa/Carbidopa, Placebo, Patching
Drug · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
7 Years to 12 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Hypertension
Interventions
Placebo, IONIS-AGT-LRx
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
48
States / cities
Anniston, Alabama • Birmingham, Alabama • Pelham, Alabama + 44 more
Conditions
Brain Injuries
Interventions
NNZ-2566, Placebo
Drug
Lead sponsor
Neuren Pharmaceuticals Limited
Industry
Eligibility
16 Years to 75 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
6
States / cities
Colton, California • Sacramento, California • Honolulu, Hawaii + 2 more
Conditions
PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE, Prevention of Pneumococcal-induced Acute Otitis Media
Interventions
Inactivated whole-cell Streptococcus pneumoniae vaccine, Placebo
Biological · Drug
Lead sponsor
Serum Life Science Europe GmbH
Industry
Eligibility
18 Years to 49 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Rochester, New York
Conditions
Staphylococcus Aureus, HIV Infections
Interventions
Mupirocin calcium ointment, 2%, Placebo ointment
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Conditions
Burns
Interventions
Selenium1, Selenium2, Placebo
Drug
Lead sponsor
Shriners Hospitals for Children
Other
Eligibility
1 Year to 18 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Congestive Heart Failure
Interventions
D-ribose, Placebo
Drug · Other
Lead sponsor
RiboCor, Inc.
Industry
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
20
States / cities
Long Beach, California • Modesto, California • Sylmar, California + 17 more
Conditions
Hypertension
Interventions
Valsartan 0.25 mg/kg, Valsartan 1.0 mg/kg, Valsartan 4.0 mg/kg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Months to 5 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
USA, New Jersey
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
Ocrelizumab, Ocrelizumab Placebo, Fingolimod, Fingolimod Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
10 Years to 17 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
10
States / cities
La Jolla, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more
Terminated Not applicable Interventional Accepts healthy volunteers

Oxybutynin and Omega-3 for OAB (Overactive Bladder)

NCT02070042
Conditions
Overactive Bladder
Interventions
Omega 3 Fatty Acid, Placebo
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Interventions
UX007, Placebo
Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
1 Year to 100 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
8
States / cities
Aurora, Colorado • Miami, Florida • Orlando, Florida + 4 more
Conditions
Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
Interventions
OSI-906, erlotinib, placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
7
States / cities
Jacksonville, Florida • Port Saint Lucie, Florida • Albany, Georgia + 4 more